UY37594A - Biomarcador inmunologico para predecir el efecto clinico de inmunoterapia del cancer - Google Patents

Biomarcador inmunologico para predecir el efecto clinico de inmunoterapia del cancer

Info

Publication number
UY37594A
UY37594A UY0001037594A UY37594A UY37594A UY 37594 A UY37594 A UY 37594A UY 0001037594 A UY0001037594 A UY 0001037594A UY 37594 A UY37594 A UY 37594A UY 37594 A UY37594 A UY 37594A
Authority
UY
Uruguay
Prior art keywords
biomarcator
preach
immune
cancer immunotherapy
clinical effect
Prior art date
Application number
UY0001037594A
Other languages
English (en)
Inventor
Hiroshi Kagamu
Original Assignee
Univ Saitama Medical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Saitama Medical filed Critical Univ Saitama Medical
Publication of UY37594A publication Critical patent/UY37594A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G01N2333/70564—Selectins, e.g. CD62
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se refiere a la predicción de la capacidad de respuesta a inmunoterapia del cáncer de un sujeto a base de la composición de células T del sujeto y un método terapéutico que usa inmunoterapia del cáncer en base a la predicción. La presente invención también proporciona un método para mejorar o mantener la capacidad de respuesta a inmunoterapia del cáncer de un sujeto.
UY0001037594A 2017-02-07 2018-02-06 Biomarcador inmunologico para predecir el efecto clinico de inmunoterapia del cancer UY37594A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017020685 2017-02-07
JP2017110069 2017-06-02

Publications (1)

Publication Number Publication Date
UY37594A true UY37594A (es) 2018-08-31

Family

ID=61527481

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037594A UY37594A (es) 2017-02-07 2018-02-06 Biomarcador inmunologico para predecir el efecto clinico de inmunoterapia del cancer

Country Status (12)

Country Link
US (3) US11293924B2 (es)
EP (2) EP4039260B1 (es)
JP (4) JP6664684B1 (es)
KR (2) KR102490278B1 (es)
CN (2) CN116712458A (es)
CA (1) CA3052027A1 (es)
IL (1) IL268524A (es)
MX (1) MX2019009386A (es)
SG (1) SG11201907102XA (es)
TW (2) TWI795386B (es)
UY (1) UY37594A (es)
WO (1) WO2018147291A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116712458A (zh) 2017-02-07 2023-09-08 学校法人埼玉医科大学 用于预测癌症免疫疗法临床效果的免疫学生物标志物
CA3074751A1 (en) * 2017-09-12 2019-03-21 ImmuneSignatures Pty Ltd Predicting responses to immunotherapy
CA3119311A1 (en) * 2018-11-09 2020-05-14 Pierian Biosciences, LLC Methods and compositions for determining the composition of a tumor microenvironment
WO2020171141A1 (ja) 2019-02-20 2020-08-27 学校法人 埼玉医科大学 がん免疫療法における長期生存を予測するための方法および組成物
US20220107324A1 (en) 2019-02-20 2022-04-07 Saitama Medical University Peripheral blood biomarker for evaluating anti-tumor immune effect of radiation therapy
EP3953712A1 (en) * 2019-04-10 2022-02-16 Universität Zürich A method for determining the likelihood of a patient being responsive to cancer immunotherapy
JP6796737B1 (ja) * 2020-06-02 2020-12-09 振武 曽 多項目自動血球計数装置
WO2022054796A1 (ja) * 2020-09-08 2022-03-17 学校法人 埼玉医科大学 癌治療に対する応答を予測するためのバイオマーカー
CN112114129A (zh) * 2020-09-25 2020-12-22 苏州大学 肿瘤特异性t细胞的检测方法
EP4219738A1 (en) * 2020-09-25 2023-08-02 Suzhou Ersheng Biopharmaceutical Co., Ltd Detection method for tumor-specific t cells
WO2022215843A1 (ko) * 2021-04-06 2022-10-13 (주)에스엠티바이오 암 환자에 대하여 자연살해세포를 이용한 면역 항암 치료의 치료 반응성을 예측하는 방법
WO2023083924A1 (en) * 2021-11-10 2023-05-19 Institut Gustave Roussy Products and uses thereof for predicting the sensitivity of a subject to cancer immunotherapy and for selecting optimized therapy
CN114354931B (zh) * 2021-12-14 2023-03-14 南方医科大学南方医院 脾肿大在确定肿瘤患者免疫检查点抑制剂治疗疗效中的应用
US12013857B2 (en) 2022-01-28 2024-06-18 Seagate Technology Llc Identifying hot items in a distributed storage system
US12013816B2 (en) 2022-01-28 2024-06-18 Seagate Technology Llc Querying metadata in a storage system
WO2023230548A1 (en) * 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
JP2006280307A (ja) * 2005-04-01 2006-10-19 Kyoto Univ 制御性ｔ細胞の製造方法
BRPI0620187A2 (pt) * 2005-12-21 2011-11-01 Sentoclone Ab método para a expansão de linfócitos t auxiliares cd4+ e/ou linfócitos t cd8+ reativos a tumor, linfócito-t reativo a tumor, composição farmacêutica, métodos para tratar um indivìduo sofrendo de uma doença de origem neoplástica e para realizar a regressão de tumor em um indivìduo, uso de linfócitos-t reativos a tumor, e, kit
US20090258025A1 (en) * 2007-07-13 2009-10-15 Genentech, Inc. Treatments and diagnostics for cancer, inflammatory disorders and autoimmune disorders
JP6230208B2 (ja) 2007-11-08 2017-11-15 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 樹状細胞／腫瘍細胞融合物および抗ｃｄ３／ｃｄ２８を使用する抗腫瘍免疫の刺激
EP2073009A1 (en) * 2007-12-19 2009-06-24 Cell Med Research GMBH Method for T, NK and NKT cells
WO2009120341A2 (en) * 2008-03-24 2009-10-01 University Of South Florida Biomarkers for predicting response to immunosuppressive therapy
US20120088678A1 (en) * 2010-09-08 2012-04-12 Sanford-Burnham Medical Research Institute Method for prediction of response to rheumatoid arthritis therapeutics
CN103502438A (zh) * 2011-03-23 2014-01-08 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
CA2840424C (en) * 2011-07-01 2022-02-01 Beckman Coulter, Inc. Regulatory t cells and methods of identifying, obtaining and using to treat immuno-based disorders
TW201413245A (zh) * 2012-09-04 2014-04-01 Univ Niigata 以表現於癌症幹細胞之分子爲標靶之癌症診斷及治療方法
EP2892558B1 (en) 2012-09-07 2019-04-10 The Trustees Of Dartmouth College Vista modulators for diagnosis and treatment of cancer
US20140288149A1 (en) 2013-03-15 2014-09-25 Graham Lord Mir-142 and antagonists thereof for treating disease
US20150118247A1 (en) 2013-10-25 2015-04-30 Nodality, Inc. Methods and compositions for immunomodulation
EA034921B1 (ru) 2014-09-28 2020-04-07 Зе Реджентс Оф Зе Юниверсити Оф Калифорния Модуляция стимулирующих и нестимулирующих миелоидных клеток
AU2016252038B2 (en) * 2015-04-20 2021-08-12 Effector Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections
JP2018519327A (ja) * 2015-06-29 2018-07-19 ベラステム・インコーポレーテッドＶｅｒａｓｔｅｍ，Ｉｎｃ． 治療用組成物、組合せ物および使用の方法
EP3417293A1 (en) 2016-02-18 2018-12-26 Institut Gustave Roussy Methods and kits for predicting the sensitivity of a subject to immunotherapy
JP7162600B2 (ja) 2017-02-06 2022-10-28 ノヴァルティス アーゲー 免疫療法に対する応答を予測する方法
CN116712458A (zh) 2017-02-07 2023-09-08 学校法人埼玉医科大学 用于预测癌症免疫疗法临床效果的免疫学生物标志物
JPWO2018212237A1 (ja) 2017-05-16 2020-03-19 伊東　恭悟 テーラーメイド型ペプチドワクチン剤に対する脳腫瘍患者の適格性を判定する方法

Also Published As

Publication number Publication date
MX2019009386A (es) 2019-11-05
JP2020073924A (ja) 2020-05-14
TW202323820A (zh) 2023-06-16
JP2022105066A (ja) 2022-07-12
KR20190112027A (ko) 2019-10-02
CN110446928A (zh) 2019-11-12
KR102490278B1 (ko) 2023-01-18
CA3052027A1 (en) 2018-08-16
TW201833551A (zh) 2018-09-16
US20200025768A1 (en) 2020-01-23
JP2024023862A (ja) 2024-02-21
US20220178933A1 (en) 2022-06-09
JP7067804B2 (ja) 2022-05-16
TWI795386B (zh) 2023-03-11
EP4039260A1 (en) 2022-08-10
CN116712458A (zh) 2023-09-08
WO2018147291A1 (en) 2018-08-16
EP4039260B1 (en) 2024-04-17
US11293924B2 (en) 2022-04-05
SG11201907102XA (en) 2019-08-27
AU2018218844A1 (en) 2019-09-19
US20230349909A1 (en) 2023-11-02
EP3580569A1 (en) 2019-12-18
CN110446928B (zh) 2023-06-20
IL268524A (en) 2019-09-26
JP2020512530A (ja) 2020-04-23
KR20230017355A (ko) 2023-02-03
JP6664684B1 (ja) 2020-03-13
KR102617574B1 (ko) 2023-12-22
EP3580569B1 (en) 2022-03-09

Similar Documents

Publication Publication Date Title
UY37594A (es) Biomarcador inmunologico para predecir el efecto clinico de inmunoterapia del cancer
CY1125260T1 (el) Παραγοντες δεσμευσης tigit και χρησεις τους
CL2021000343A1 (es) Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128)
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
EA201992131A1 (ru) Высокоаффинные специфичные к mage-a1 tcr и их применение
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
BR112018015485A2 (pt) imunoglobulina fabs-in-tandem e usos da mesma
CO2020014345A2 (es) Anticuerpos específicos para gucy2c y sus usos
CL2017000278A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
BR112016030670A2 (pt) "imunocitoquina"
TWD189787S (zh) 鞋子
ECSP19015192A (es) Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos
CO2017004932A2 (es) Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva
CU20160101A7 (es) Inmunoglobulina con fab en tándem
BR112017001242A2 (pt) tratamento de câncer usando um receptor antigênico quimérico a cd33
EA201692477A1 (ru) Композиции и способы применения для лечения метаболических расстройств
BR112017009671A2 (pt) inibidores de ezh2 e usos destes
BR112016028891A2 (pt) processos de trens de sementes e usos dos mesmos
BR112016012860A2 (pt) Compostos de biarila úteis no tratamento de doenças humanas em oncologia, neurologia e imunologia
AR104664A1 (es) Conjugados de fármacos con anticuerpos contra la cadherina 6 (anti-cdh6)
BR112017012381A2 (pt) imunoterapia para doença angiogênica
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
CO2018012497A2 (es) Anticuerpos de interferón beta y usos de los mismos
CL2021001593A1 (es) Tubulisinas y conjugados de proteína-tubulisina
BR112019010128A2 (pt) proteínas de ligação a antígeno anti-gitr e métodos de uso das mesmas

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20201204